

CITATION REPORT

List of articles citing

Genes for schizophrenia? Recent findings and their pathophysiological implications

DOI: 10.1016/s0140-6736(03)12379-3
Lancet, The, 2003, 361, 417-9.

Source: <https://exaly.com/paper-pdf/35484767/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
533	Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome. 2003 , 5, E29		16
532	Glutamate receptors and transporters in the hippocampus in schizophrenia. 2003 , 1003, 94-101		120
531	Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. 2003 , 1003, 318-27		356
530	Emerging insights on the neuroanatomy of schizophrenia. 2003 , 1, 28-34		
529	Brain-derived neurotrophic factor as a potential risk locus for bipolar disorder: evidence, limitations, and implications. 2003 , 5, 469-76		37
528	The genetics of schizophrenia: glutamate not dopamine?. 2003 , 480, 177-84		70
527	Pharmacogenomics of schizophrenia: Towards personalized psychiatry. 2003 , 60, 71-74		2
526	Expression of NMDA receptor NR1, NR2A and NR2B subunit mRNAs during development of the human hippocampal formation. 2003 , 18, 1197-205		99
525	Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. 2003 , 18, 1706-10		144
524	Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis. 2003 , 8, 821-831		166
523	Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. <i>Lancet, The</i> , 2003 , 361, 1511-7	40	402
522	TRISTAN study gives clear message. <i>Lancet, The</i> , 2003 , 361, 1517	40	
521	Genes for schizophrenia. <i>Lancet, The</i> , 2003 , 361, 1828-9; author reply 1829-30	40	2
520	Genes for schizophrenia. <i>Lancet, The</i> , 2003 , 361, 1829; author reply 1829-30	40	7
519	Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2003 , 361, 2024-31	40	728
518	The synaptic hypothesis of schizophrenia. 2003 , 39, 205-16		138
517	Bringing order to the glutamate chaos in schizophrenia. 2003 , 40, 881-4		344

516	Schizophrenias and epilepsies: why? when? how?. 2003 , 4, 474-82	17
515	Polymorphically duplicated genes: their relevance to phenotypic variation in humans. 2003 , 35, 308-15	68
514	Fifty years of the double helix and its impact on psychiatry. 2003 , 37, 657-61	6
513	Invited commentary: Gaining traction on the epidemiologic landscape of schizophrenia. 2003 , 158, 301-4	13
512	Presidential address. Science as a way of life: perplexities of a physician-scientist. 2003 , 300, 1680-5	39
511	Recent advances in the genetics of schizophrenia. 2003 , 12 Spec No 2, R125-33	120
510	Psychiatric drug discovery and development. 2003 , 12, 1571-5	6
509	DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. 2003 , 12, 1591-608	311
508	Elucidating the pathogenesis of schizophrenia. 2003 , 327, 632-3	12
507	From pharmacotherapy to pathophysiology: emerging mechanisms of apolipoprotein D in psychiatric disorders. 2003 , 3, 408-18	35
506	Of genes and twins. 2003 , 33, 763-8	3
505	The causes of schizophrenia: neurodevelopment and other risk factors. 2003 , 9, 442-54	19
504	Schizophrenia: The New Evidence. 2003 , 8, 31-34	0
503	The genetics of schizophrenia: chromosomal deletions, attentional disturbances, and spectrum boundaries. 2003 , 160, 1549-53	23
502	SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSIS. 2003 , 223-233	20
501	How does drug abuse interact with familial and developmental factors in the etiology of schizophrenia?. 2004 , 248-270	2
500	Schizophrenia and oral healthcare. 2004 , 31, 510-2, 514-5	1
499	The etiopathogenesis of schizophrenias. 2004 , 37 Suppl 2, S103-12	11

498	Nature and nurture interplay: schizophrenia. 2004 , 31 Suppl 2, S189-93	23
497	The search for novel antipsychotics: pharmacological and molecular targets. 2004 , 8, 631-41	16
496	Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. 2004 , 29, 1259-69	220
495	[Schizophrenia]. 2004 , 72, 164-74	0
494	[New strategies in schizophrenia: impact of endophenotypes]. 2004 , 31 Suppl 2, S194-9	
493	The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective. 2004 , 359, 943-64	82
492	Santorini Biologie Prospective Conference 2004 From Human Genetic Variations to Prediction of Risks and Responses to the Environment[Santorini, Greece, September 30October 4, 2004. 2004 , 42,	
491	Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. 2004 , 61, 544-55	298
490	Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). 2004 , 61, 336-44	155
489	Haplotype analysis and identification of genes for a complex trait: examples from schizophrenia. 2004 , 36, 322-31	11
488	Schizophrenia, vitamin D, and brain development. 2004 , 59, 351-80	55
487	Genetics of schizophrenia: implications for treatment. 2004 , 4, 725-31	4
486	NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. 2004 , 59, 491-515	104
485	NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. 2004 , 101, 8467-72	322
484	E pluribus unum, ex uno plura: quantitative and single-gene perspectives on the study of behavior. 2004 , 27, 79-105	30
483	Pathways to schizophrenia: the impact of environmental factors. 2004 , 7 Suppl 1, S7-S13	128
482	Myospryn is a novel binding partner for dysbindin in muscle. 2004 , 279, 10450-8	53
481	The potential impact of genetic counseling for mental illness. 2005 , 67, 134-42	51

480	Association of the XBP1-116C/G polymorphism with schizophrenia in the Japanese population. 2004 , 58, 438-40	38
479	Association and linkage analysis of RGS4 polymorphisms with schizophrenia and bipolar disorder in Brazil. 2005 , 4, 45-50	47
478	Resolving schizophrenia's CATCH22. 2004 , 36, 674-5	13
477	Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. 2004 , 3, 353-9	898
476	Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. 2004 , 9, 299-307	236
475	The molecular genetics of schizophrenia: new findings promise new insights. 2004 , 9, 14-27	257
474	No association with the neuregulin 1 haplotype to Japanese schizophrenia. 2004 , 9, 126-7	90
473	Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. 2004 , 9, 698-704	142
472	Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. 2004 , 9, 442-73	575
471	The behavioural phenotype in velo-cardio-facial syndrome. 2004 , 48, 524-30	23
470	The GABA-glutamate connection in schizophrenia: which is the proximate cause?. 2004 , 68, 1507-14	156
469	Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia. 2004 , 1021, 64-76	98
468	[In search of susceptibility genes for schizophrenia]. 2004 , 116, 827-33	3
467	The genetic relationship of personality to major depression and schizophrenia. 2004 , 6, 43-50	28
466	The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. 2004 , 174, 151-62	510
465	Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. 2004 , 174, 39-44	144
464	Postgenomic psychiatry: Great hopes or great hype?. 2004 , 6, 75-76	2
463	Approaches for adolescents with an affected family member with schizophrenia. 2004 , 6, 296-302	7

462	The genes for schizophrenia: finally a breakthrough?. 2004 , 6, 303-12	34
461	The genes for schizophrenia: Finally a breakthrough?. 2004 , 2, 57-66	
460	Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. 2004 , 51, 112-8	75
459	Confirming RGS4 as a susceptibility gene for schizophrenia. 2004 , 125B, 50-3	114
458	Linkage disequilibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: findings from identity by descent haplotype sharing analysis. 2004 , 128B, 65-70	40
457	Detecting epistatic interactions contributing to quantitative traits. 2004 , 27, 141-52	146
456	Role of pharmacogenomics in drug development. 2004 , 62, 86-96	6
455	Population genomics of drug response. 2004 , 4, 73-82	4
454	Genomics and genealogy provide an Icelandic springboard into the human gene pool. 2004 , 13, 21-27	0
453	Structures of the Escherichia coli PutA proline dehydrogenase domain in complex with competitive inhibitors. 2004 , 43, 12539-48	64
452	Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. 2004 , 13, 2699-708	307
451	Bedside to Bench and Back Again: Translational Neuroscience Research and Geriatric Psychiatry. 2004 , 12, 122-125	5
450	Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. 2004 , 55, 976-80	132
449	Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. 2004 , 55, 971-5	133
448	The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. 2004 , 55, 965-70	188
447	Epigenetic studies of genomic retroelements in major psychosis. 2004 , 67, 95-106	23
446	Mismatch negativity potentials and cognitive impairment in schizophrenia. 2004 , 69, 203-17	220
445	Mutation analysis of the human dystrobrevin-binding protein 1 gene in schizophrenic patients. 2004 , 71, 185-9	14

444	Meta-analysis of the P300 and P50 waveforms in schizophrenia. 2004 , 70, 315-29		448
443	A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. 2004 , 71, 405-16		374
442	Association of G72/G30 with schizophrenia in the Chinese population. 2004 , 319, 1281-6		91
441	Neuron-glia interactions clarify genetic-environmental links in mental illness. 2004 , 27, 294-7		21
440	Schizophrenia genetics: dysbindin under the microscope. 2004 , 27, 516-9		59
439	Short- and long-range attraction of cortical GABAergic interneurons by neuregulin-1. 2004 , 44, 251-61		342
438	MK-801 upregulates the expression of d-amino acid oxidase mRNA in rat brain. 2004 , 131, 141-4		20
437	Association of DAAO with schizophrenia in the Chinese population. 2004 , 369, 228-33		50
436	Is there an association between the use of heeled footwear and schizophrenia?. 2004 , 63, 740-7		8
435	What's new in □The neurochemistry of schizophrenia. 2004 , 32, 1-4		
434	Schizophrenia. 2004 , 32, 21-25		
433	Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. 2004 , 74, 1057-63		121
432	Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. <i>Lancet, The</i> , 2004 , 363, 1187-92	40	734
431	Million women study most wanted in 2003. <i>Lancet, The</i> , 2004 , 363, 1192	40	78
430	Schizophrenia. <i>Lancet, The</i> , 2004 , 363, 2063-72	40	652
429	Primary open-angle glaucoma: pathophysiology and treatment. <i>Lancet, The</i> , 2004 , 364, 1311-2	40	41
428	Schizophrenia. <i>Lancet, The</i> , 2004 , 364, 1312	40	2
427	Schizophrenia. <i>Lancet, The</i> , 2004 , 364, 1312-3	40	17

426	Reduced spinophilin but not microtubule-associated protein 2 expression in the hippocampal formation in schizophrenia and mood disorders: molecular evidence for a pathology of dendritic spines. 2004 , 161, 1848-55	121
425	Genetics of bipolar disorder: where do we stand?. 2004 , 161, 595-7	29
424	Have schizophrenia genes been found?. 2004 , 17, 107-113	6
423	Pathways of genetic influences on psychopathology. 2004 , 12, 19-33	26
422	Focus on clozapine: a new explanation for its atypical character. 2005 , 8, 311-3	2
421	Behavioral and psychiatric disorder in velo-cardio-facial syndrome. 2005 , 135-146	3
420	Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. 2005 , 62, 371-8	127
419	Bases biochimiques et neurobiologiques de la psychiatrie. 2005 , 2, 1-23	1
418	Psychiatric disorders in parents of children with autism: a meta-analysis. 2005 , 46, 69-83	118
417	Towards an understanding of unique and shared pathways in the psychopathophysiology of ADHD. 2005 , 8, 132-40	112
416	Fine mapping of a schizophrenia susceptibility locus at chromosome 6q23: increased evidence for linkage and reduced linkage interval. 2005 , 13, 763-71	37
415	Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. 2005 , 10, 40-68; image 5	1654
414	Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients. 2005 , 10, 213-9	86
413	Phenotype of schizophrenia: a review and formulation. 2005 , 10, 27-39	219
412	Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework. 2005 , 10, 6-13	199
411	BDNF gene is a risk factor for schizophrenia in a Scottish population. 2005 , 10, 208-12	213
410	Expanding the 'central dogma': the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia. 2005 , 10, 69-78	76
409	Tumor necrosis factor promoter haplotype associated with schizophrenia reveals a linked locus on 1q44. 2005 , 10, 375-83	20

408	The neurodevelopmental model of schizophrenia: update 2005. 2005 , 10, 434-49	749
407	Genomic influences on schizophrenia-related neurotransmitter systems. 2005 , 37, 322-8	9
406	Association analysis of the RGS4 gene in Han Chinese and Scottish populations with schizophrenia. 2005 , 4, 444-8	36
405	Neurogenetics: insights into degenerative diseases and approaches to schizophrenia. 2005 , 5, 3-14	9
404	Mice lacking D-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801. 2005 , 1033, 210-5	56
403	Structural violence and schizophrenia. 2005 , 61, 721-30	98
402	Schizophrenia: genes at last?. 2005 , 21, 518-25	241
401	Systematic mutation analysis of KIAA0767 and KIAA1646 in chromosome 22q-linked periodic catatonia. 2005 , 5, 36	6
400	Genetics of schizophrenia. 2005 , 4, 14-17	2
399	The neurochemistry of schizophrenia. 2005 , 4, 21-25	2
398	Epidemiology and risk factors. 2005 , 4, 7-10	1
397	Fine mapping of a region on chromosome 8p gives evidence for a QTL contributing to individual differences in an anxiety-related personality trait: TPQ harm avoidance. 2005 , 132B, 104-8	22
396	The highly efficacious actions of N-desmethylozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?. 2005 , 178, 451-60	95
395	N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. 2005 , 179, 30-53	193
394	Stereological studies of capillary length density in the frontal cortex of schizophrenics. 2005 , 109, 510-8	58
393	The nature of brain abnormalities in schizophrenia: What do we really know?. 2005 , 3, 48-52	
392	Schizophrenia: an update and review. 2005 , 14, 329-40	48
391	Inhibition of soybean urease by triketone oximes. 2005 , 70, 40-54	9

390	D-amino acid oxidase: structure, catalytic mechanism, and practical application. 2005 , 70, 40-54	67
389	Adolescents and young adults with 22q11 deletion syndrome: psychopathology in an at-risk group. 2005 , 186, 115-20	147
388	Schizophrenia. 2005 , 1327-1336	
387	COMPLEX GENETIC TRAITS. 2005 , 77-118	1
386	Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. 2005 , 2, e263	78
385	Toward a philosophical structure for psychiatry. 2005 , 162, 433-40	345
384	The XIIth World Congress of Psychiatric Genetics. October 9-13, 2004, Dublin, Ireland. 2005 , 6, 199-204	
383	Neuroimaging and human genetics. 2005 , 67, 325-83	19
382	Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. 2005 , 162, 1824-32	137
381	Psychiatric genetics: a methodologic critique. 2005 , 162, 3-11	87
380	Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. 2005 , 63, 41-82	43
379	Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. 2005 , 25, 4974-84	173
378	Schizophrenia: a genetic disorder of the synapse?. 2005 , 330, 158-9	53
377	Discovering the Genetics of Complex Disorders Through Integration of Genomic Mapping and Transcriptional Profiling. 2005 , 1, 21-34	5
376	Dysfunction of Glia-Neuron Communication in Pathophysiology of Schizophrenia. 2005 , 1, 151-163	62
375	Genetics, Perinatal Insult and Schizophrenia: The Mechanism Underlying an Increased Prevalence of Perinatal Complications Among Individuals with a Diagnosis of Schizophrenia?. 2005 , 1, 139-150	11
374	The long and winding road of schizophrenia research. 2005 , 14, 179-83	4
373	Would regional government have been good for your health?. 2005 , 330, 159-60	1

372	Size of burden of schizophrenia and psychotic disorders. 2005 , 15, 399-409	406
371	DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. 2005 , 26, 1109-18	356
370	History, aetiology and symptomatology of schizophrenia. 2005 , 4, 2-6	1
369	S.12.02 Genes and subtypes of schizophrenia. 2005 , 15, S332-S333	
368	S.12.04 An intermediate phenotype strategy in the search for genetic susceptibility factors. 2005 , 15, S333	
367	S.12.05 Genes to predict antipsychotic weight gain. 2005 , 15, S333	
366	S.13.01 What outcomes, what interventions - the methodology. 2005 , 15, S333-S334	1
365	FOXP2 polymorphisms in patients with schizophrenia. 2005 , 73, 253-6	21
364	Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. 2005 , 14, 1947-54	156
363	The epidemiologic approach to pharmacogenomics. 2005 , 5, 1-20	21
362	Future contributions on genetics. 2005 , 6 Suppl 2, 49-55	1
361	Neurodevelopment, neuroplasticity, and new genes for schizophrenia. 2005 , 147, 319-45	100
360	The genetics of schizophrenia and bipolar disorder: dissecting psychosis. 2005 , 42, 193-204	406
359	Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. 2006 , 32, 9-16	385
358	Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. 2005 , 139, 317-32	78
357	Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. 2005 , 388, 126-31	41
356	Association of the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. 2005 , 328, 809-15	57
355	Genomic approaches to schizophrenia. 2005 , 27 Suppl A, S2-7	19

354	Bases biochimiques et neurobiologiques de la psychiatrie. 2005 , 2, 4-39	
353	Developmental Vitamin D3 deficiency alters the adult rat brain. 2005 , 65, 141-8	217
352	Eye tracking in schizophrenia: does the antisaccade task measure anything that the smooth pursuit task does not?. 2005 , 136, 181-8	17
351	Developing therapeutics for schizophrenia and other psychotic disorders. 2005 , 2, 579-89	19
350	Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. 2005 , 57, 433-6	134
349	Decreased hippocampal expression of the susceptibility gene PPP3CC and other calcineurin subunits in schizophrenia. 2005 , 57, 702-10	62
348	Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. 2005 , 57, 1493-503	131
347	A missense polymorphism (H204R) of a Rho GTPase-activating protein, the chimerin 2 gene, is associated with schizophrenia in men. 2005 , 73, 383-5	23
346	Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. 2005 , 73, 159-72	154
345	Possible association of the MAG locus with schizophrenia in a Chinese Han cohort of family trios. 2005 , 75, 11-9	39
344	What causes the onset of psychosis?. 2005 , 79, 23-34	137
343	Cortical gene expression in the neonatal ventral-hippocampal lesion rat model. 2005 , 77, 261-70	26
342	Association between polymorphism of the SNAP29 gene promoter region and schizophrenia. 2005 , 78, 339-41	16
341	Risk for schizophrenia--broadening the concepts, pushing back the boundaries. 2005 , 79, 5-13	68
340	Premorbid indicators and risk for schizophrenia: a selective review and update. 2005 , 79, 45-57	105
339	Trivial and non-trivial machines in the animal and in man. 2005 , 34, 508-520	
338	Aktuelle Aspekte genetischer Forschung bei Schizophrenie. 2006 , 69-79	
337	Psychopharmacogenetics. 2006 ,	5

336	Early Life Origins of Health and Disease. 2006 ,	7
335	Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. 2006 , 79, 586-92	189
334	Negative pressure therapy in diabetic foot wounds [Authors' reply. <i>Lancet, The</i> , 2006 , 367, 726-727	40 4
333	Speciation and schizophrenia: literature anticipates science. <i>Lancet, The</i> , 2006 , 367, 727	40
332	[Biological models of schizophrenia: an update]. 2006 , 32, 446-51	2
331	Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. 2006 , 59, 546-54	362
330	Significant association between the genetic variations in the 5' end of the N-methyl-D-aspartate receptor subunit gene GRIN1 and schizophrenia. 2006 , 59, 747-53	51
329	Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. 2006 , 60, 132-40	373
328	Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. 2006 , 59, 1180-8	97
327	Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. 2006 , 60, 1224-30	69
326	Inherited auditory-cortical dysfunction in twin pairs discordant for schizophrenia. 2006 , 60, 612-20	79
325	Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. 2006 , 59, 1198-207	271
324	Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. 2006 , 84, 253-71	100
323	Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. 2006 , 86, 1-14	101
322	The G72/G30 gene complex and cognitive abnormalities in schizophrenia. 2006 , 31, 2022-32	115
321	Interleukin-10 -1082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study. 2006 , 394, 1-4	19
320	RGS4 polymorphisms and risk of schizophrenia: an association study in Han Chinese plus meta-analysis. 2006 , 406, 122-7	26
319	Significant linkage and association between a functional (GT) _n polymorphism in promoter of the N-methyl-D-aspartate receptor subunit gene (GRIN2A) and schizophrenia. 2006 , 409, 80-2	38

318	Creativity and evolution. 2006 , 1296, 95-105	1
317	The schizophrenic faces of PICK1. 2006 , 27, 574-9	37
316	Genetic Heterogeneity, Modifier Genes, and Quantitative Phenotypes in Psychiatric Illness: Searching for a Framework. 2006 , 4, 423-430	2
315	Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. 2006 , 21 Suppl 2, S11-5	76
314	Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. 2006 , 63, 366-73	124
313	Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. 2006 , 60, 102-8	27
312	Psychosis pathways converge via D2high dopamine receptors. 2006 , 60, 319-46	252
311	II. Genotype-environment interaction in the schizophrenia spectrum: qualitative observations. 2006 , 45, 435-47	10
310	Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. 2006 , 12, 824-8	479
309	Molecular genetic studies of schizophrenia. 2006 , 14, 669-80	136
308	AHI1, a pivotal neurodevelopmental gene, and C6orf217 are associated with susceptibility to schizophrenia. 2006 , 14, 1111-9	64
307	Association study of the G-protein signaling 4 (RGS4) and proline dehydrogenase (PRODH) genes with schizophrenia: a meta-analysis. 2006 , 14, 1130-5	33
306	Extreme population differences across Neuregulin 1 gene, with implications for association studies. 2006 , 11, 66-75	79
305	A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. 2006 , 11, 286-300	185
304	Family-based association study of Epsin 4 and Schizophrenia. 2006 , 11, 395-9	15
303	MPZL1/PZR, a novel candidate predisposing schizophrenia in Han Chinese. 2006 , 11, 748-51	8
302	Subtyping schizophrenia: implications for genetic research. 2006 , 11, 815-36	191
301	Six degrees of separation: on the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and NMDA receptors. 2006 , 11, 981-3	27

300	Chromosomal fragile sites in schizophrenic patients. 2006 , 42, 810-817	0
299	Glutamate and schizophrenia: beyond the dopamine hypothesis. 2006 , 26, 365-84	658
298	Failure to find association between TRAR4 and schizophrenia in the Chinese Han population. 2006 , 113, 381-5	19
297	Genome scans and gene expression microarrays converge to identify gene regulatory loci relevant in schizophrenia. 2006 , 119, 558-70	33
296	The effect of gender in diagnosing early schizophrenia--an experimental case simulation study. 2006 , 41, 549-55	12
295	Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. 2006 , 10, 221-33	64
294	Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia. 2006 , 22, 624-37	79
293	DISC1 immunoreactivity at the light and ultrastructural level in the human neocortex. 2006 , 497, 436-50	100
292	A preliminary comparison of the hopes of researchers, clinicians, and families for the future ethical use of genetic findings on schizophrenia. 2006 , 141B, 110-5	68
291	The genomic era and perceptions of psychotic disorders: genetic risk estimation, associations with reproductive decisions and views about predictive testing. 2006 , 141B, 926-8	50
290	Chromosome 22 deletion syndrome and schizophrenia. 2006 , 73, 1-27	11
289	Haplotypes spanning SPEC2, PDZ-GEF2 and ACSL6 genes are associated with schizophrenia. 2006 , 15, 3329-42	38
288	The psychosis proneness: psychosis persistence model as an explanation for the association between urbanicity and psychosis. 2006 , 15, 252-257	13
287	Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. 2006 , 16, 93-105	72
286	Adrenergic modulation of NMDA receptors in prefrontal cortex is differentially regulated by RGS proteins and spinophilin. 2006 , 103, 18338-43	68
285	Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. 2006 , 15, 1995-2002	239
284	Schizophrenie und verwandte Störungen in Neurobiologie. 2006 , 345-386	2
283	RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. 2007 , 71, 1030-9	57

282 Neurogenetics of Psychiatric Disorders. **2007**,

281	G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. 2007 , 175, 917-22	59
280	Volume, neuron density and total neuron number in five subcortical regions in schizophrenia. 2007 , 130, 678-92	141
279	Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE review and meta-analysis. 2007 , 9, 4-8	61
278	The genomic era and serious mental illness: a potential application for psychiatric genetic counseling. 2007 , 58, 254-61	42
277	[Impairments of action control in the context of neuropsychological findings in schizophrenia]. 2007 , 75, 607-16	2
276	Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. 2007 , 27, 4519-29	153
275	Dopamine and Glutamate Hypotheses of Schizophrenia. 2007 ,	
274	Resolving the latent structure of schizophrenia endophenotypes using expectation-maximization-based finite mixture modeling. 2007 , 116, 16-29	56
273	How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. 2007 , 164, 13-21	97
272	Case-control association study of the 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) gene and schizophrenia in the Han Chinese population. 2007 , 416, 113-6	10
271	Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects. 2007 , 416, 96-100	34
270	Risk factors for schizophrenia--all roads lead to dopamine. 2007 , 17 Suppl 2, S101-7	78
269	Does Schizophrenia Exist?. 2007 , 63, 104-6	
268	Schizophrenia endophenotypes as treatment targets. 2007 , 11, 1189-206	39
267	Overview of animal models of schizophrenia. 2007 , Chapter 9, Unit 9.24	18
266	Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?. 2007 , 21, 283-301	85
265	Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. 2007 , 21, 699-714	21

264	Potential genetic variants in schizophrenia: a Bayesian analysis. 2007 , 8, 12-22	23
263	The genetic deconstruction of psychosis. 2007 , 33, 905-11	215
262	Association analysis of G72/G30 polymorphisms with schizophrenia in the Korean population. 2007 , 96, 119-24	17
261	Association study between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia: a meta-analysis. 2007 , 96, 112-8	30
260	Molecular Genetics of Schizophrenia. 2007 ,	
259	Coping with stressors: racism and migration. 550-560	1
258	Major psychiatric disorders in adult life. 454-468	
257	Phenomenology and Clinical Science of Schizophrenia. 2007 ,	
256	Family-based association study of neuregulin-1 gene and psychosis in a Spanish sample. 2007 , 144B, 954-7	21
255	Cortical mapping of genotype-phenotype relationships in schizophrenia. 2007 , 28, 519-32	20
254	Neuregulin 1 (8p12) and childhood-onset schizophrenia: susceptibility haplotypes for diagnosis and brain developmental trajectories. 2007 , 12, 195-205	97
253	Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. 2007 , 12, 854-69	218
252	Significant correlation in linkage signals from genome-wide scans of schizophrenia and schizotypy. 2007 , 12, 958-65	70
251	d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. 2007 , 26, 1657-69	143
250	Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. 2007 , 53, 260-70	95
249	Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia. 2007 , 54, 92-112	138
248	Physiological functions of D-amino acid oxidases: from yeast to humans. 2007 , 64, 1373-94	267
247	Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophrenia. 2007 , 114, 239-48	21

246	No association between the genetic polymorphisms in the RTN4R gene and schizophrenia in the Chinese population. 2007 , 114, 249-54	20
245	Association study of polymorphisms in post-synaptic density protein 95 (PSD-95) with schizophrenia. 2007 , 114, 423-6	13
244	How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. 2007 , 114, 527-37	41
243	Two-stage designs to identify the effects of SNP combinations on complex diseases. 2008 , 53, 739-746	10
242	Kraepelin, biological psychiatry, and beyond. 2008 , 258 Suppl 2, 29-32	21
241	Common risk genes for affective and schizophrenic psychoses. 2008 , 258 Suppl 2, 37-40	38
240	Candidate genes and the behavioral phenotype in 22q11.2 deletion syndrome. 2008 , 14, 26-34	58
239	Genome-wide linkage scan, fine mapping, and haplotype analysis in a large, inbred, Arab Israeli pedigree suggest a schizophrenia susceptibility locus on chromosome 20p13. 2008 , 147B, 209-15	14
238	High-throughput screening assay for D-amino acid oxidase. 2008 , 374, 405-10	9
237	D-amino acid oxidase: physiological role and applications. 2008 , 73, 1511-8	50
236	An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. 2008 , 13, 1060-8	82
235	The myelin-pathogenesis puzzle in schizophrenia: a literature review. 2008 , 13, 245-60	82
234	Altered gene expression in the superior temporal gyrus in schizophrenia. 2008 , 9, 199	61
233	Association of the gene encoding neurogranin with schizophrenia in males. 2008 , 42, 125-33	43
232	No significant association between the genetic polymorphisms in the GSK-3 beta gene and schizophrenia in the Chinese population. 2008 , 42, 365-70	13
231	Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. 2008 , 42, 278-88	74
230	History, aetiology, and symptomatology of schizophrenia. 2008 , 7, 404-409	6
229	Genetics of schizophrenia. 2008 , 7, 415-420	1

228	The neurochemistry of schizophrenia. 2008 , 7, 425-429	6
227	Implication of neuronal Ca ²⁺ -sensor protein VILIP-1 in the glutamate hypothesis of schizophrenia. 2008 , 32, 162-75	17
226	Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F. 2008 , 48, 997-1013	31
225	The emperors of the schizophrenia polygene have no clothes. 2008 , 38, 1681-5	37
224	Expression of Kruppel-like factor 5 gene in human brain and association of the gene with the susceptibility to schizophrenia. 2008 , 100, 291-301	26
223	Genetic variation in the DAOA gene complex: impact on susceptibility for schizophrenia and on cognitive performance. 2008 , 103, 169-77	27
222	Shared gene expression alterations in schizophrenia and bipolar disorder. 2008 , 64, 89-97	141
221	Aspects of Piaget's cognitive developmental psychology and neurobiology of psychotic disorders - an integrative model. 2008 , 71, 426-33	10
220	Investigation of variants in the promoter region of PIK3C3 in schizophrenia. 2008 , 437, 42-4	12
219	A genetic association study of the FXD domain containing ion transport regulator 6 (FXD6) gene, encoding phosphohippin, in susceptibility to schizophrenia in a Japanese population. 2008 , 438, 70-5	9
218	DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. 2008 , 440, 150-4	14
217	No genetic association between NCAM1 gene polymorphisms and schizophrenia in the Chinese population. 2008 , 32, 1633-6	8
216	Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes. 2008 , 68, 436-61	86
215	Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients. 2008 , 18, 333-8	22
214	Foreword. Content versus delivery: challenges and options in the treatment of schizophrenia. 2008 , 18 Suppl 3, v-vi	
213	Schizophrenia: from developmental deviance to dopamine dysregulation. 2008 , 18 Suppl 3, S129-34	104
212	Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. 2008 , 102, 283-94	33
211	Brain neuroplasticity in healthy, hyperactive and psychotic children: insights from neuroimaging. 2008 , 33, 181-97	94

210	Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). 2008 , 326, 209-17	188
209	Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder. 2008 , 33, 933-45	55
208	Increased alpha-defensins as a blood marker for schizophrenia susceptibility. 2008 , 7, 1204-13	36
207	New Approaches to Treatment of Schizophrenia by Enhancing N-methyl-d-aspartate Neurotransmission. 2008 , 3,	
206	Neurobiology of the early course of schizophrenia. 2008 , 8, 1093-100	9
205	Role of glutamate in schizophrenia: integrating excitatory avenues of research. 2008 , 8, 1389-406	39
204	[Schizophrenia as a brain disorder and its development]. 2008 , 76 Suppl 1, S63-7	5
203	EVestG: a diagnostic measure for schizophrenia. 2008 , 2008, 4142-5	4
202	The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. 2008 , 22, 308-22	136
201	Genetic epidemiology. 80-94	
200	Is brain banking of psychiatric cases valuable for neurobiological research?. 2008 , 63, 255-66	18
199	Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia. 2008 , 1, 6	193
198	Schizophrenia and related disorders. 284-319	2
197	Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia. 2009 , 23, 937-43	10
196	Phenotyping psychosis: room for neurocomputational and content-dependent cognitive endophenotypes?. 2009 , 14, 451-72	5
195	Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population. 2009 , 54, 98-107	88
194	Beneficial Effects of Fish Oil on Human Brain. 2009 ,	42
193	Evidence for an interaction of schizophrenia susceptibility loci on chromosome 6q23.3 and 10q24.33-q26.13 in Arab Israeli families. 2009 , 150B, 914-25	9

192	Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. 2009 , 30, 241-55	195
191	Microvessel length density, total length, and length per neuron in five subcortical regions in schizophrenia. 2009 , 117, 409-21	30
190	Cytoarchitecture cérébrale dans la schizophrénie. 2009 , 7, 23-30	2
189	Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex. 2009 , 380, 383-97	14
188	Brain banking: opportunities, challenges and meaning for the future. 2009 , 10, 70-8	90
187	DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study. 2009 , 59, 142-50	31
186	Prepulse inhibition and genetic mouse models of schizophrenia. 2009 , 204, 282-94	153
185	In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. 2009 , 204, 32-66	104
184	Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features. 2009 , 109, 94-7	34
183	Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. 2009 , 10, 127-55	54
182	Dissecting the Molecular Causes of Schizophrenia. 2009 , 51-79	
181	Drugs in development for the treatment of schizophrenia. 2009 , 18, 1103-18	23
180	Prenatal viral infection of mice at E16 causes changes in gene expression in hippocampi of the offspring. 2009 , 19, 648-53	37
179	A putative high risk diplotype of the G72 gene is in healthy individuals associated with better performance in working memory functions and altered brain activity in the medial temporal lobe. 2009 , 45, 1002-8	32
178	The neurodevelopmental hypothesis of schizophrenia, revisited. 2009 , 35, 528-48	560
177	Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. 2009 , 70, 1416-23	91
176	Disease versus dimension in diagnosis. 2010 , 55, 59-64	5
175	Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. 2010 , 128, 419-32	402

174	Exploring the knowledge contained in neuroimages: statistical discriminant analysis and automatic segmentation of the most significant changes. 2010 , 49, 105-15	4
173	Detection of SNP-SNP interactions in trios of parents with schizophrenic children. 2010 , 34, 396-406	18
172	Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. 2010 , 34, 958-77	124
171	Cytosolic protein interactions of the schizophrenia susceptibility gene dysbindin. 2010 , 113, 1491-503	31
170	The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. 2010 , 15, 122-37	115
169	Molecular networks in drug discovery. 2010 , 38, 143-56	32
168	Modulation of Central Nitric Oxide as a Therapeutic Strategy for Schizophrenia. 2010 , 20, 115-119	5
167	Neurobiology and etiology of primary schizophrenia: current status. 3-15	3
166	Fine mapping of AHI1 as a schizophrenia susceptibility gene: from association to evolutionary evidence. 2010 , 24, 3066-82	32
165	Nucleocytoplasmic shuttling of dysbindin-1, a schizophrenia-related protein, regulates synapsin I expression. 2010 , 285, 38630-40	18
164	Expressions of neuregulin 1beta and ErbB4 in prefrontal cortex and hippocampus of a rat schizophrenia model induced by chronic MK-801 administration. 2010 , 2010, 859516	15
163	Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: A review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. 2010 , 53, 878-92	73
162	Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome. 2010 , 83, 132-9	65
161	[The genetics of schizophrenia: back to the clinic?]. 2010 , 36, 91-3	2
160	Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. 2010 , 92, 370-85	228
159	No association between EGR gene family polymorphisms and schizophrenia in the Chinese population. 2010 , 34, 506-9	12
158	Is the EFNB2 locus associated with schizophrenia? Single nucleotide polymorphisms and haplotypes analysis. 2010 , 180, 5-9	14
157	Serotonin and Schizophrenia. 2010 , 21, 585-620	11

156	Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. 2011 , 43, 1228-31	231
155	The Hypoxic Rat Model for Obstetric Complications in Schizophrenia. 2011 , 93-111	
154	DISC1: Structure, Function, and Therapeutic Potential for Major Mental Illness. 2011 , 2, 609-632	89
153	Discovery and development of integrative biological markers for schizophrenia. 2011 , 95, 686-702	25
152	Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway. 2011 , 177, 159-69	38
151	Schizophrenia. 2011 , 1501-1511	1
150	Role of Thalamic Projection in NMDA Receptor-Induced Disruption of Cortical Slow Oscillation and Short-Term Plasticity. 2011 , 2, 14	47
149	The Role of Microbial Agents in the Etiology of Schizophrenia: An Infectious Hypothesis for Psychosis?. 2011 , 7, 57-63	
148	Classical Genetic Studies of Schizophrenia. 2011 , 245-268	1
147	Clozapine and N-methyl-D-aspartate have positive modulatory actions on their respective discriminative stimulus properties in C57BL/6 mice. 2011 , 650, 579-85	2
146	D-amino acids in normal ageing and pathogenesis of neurodegenerative diseases. 2011 , 5, 100-114	16
145	No association of the YWHA gene with schizophrenia, major depressive disorder or bipolar disorder in the Han Chinese population. 2011 , 41, 557-64	9
144	An Update on the Epidemiology of Schizophrenia with a Special Reference to Clinically Important Risk Factors. 2011 , 9, 39-59	3
143	Familial liability, obstetric complications and childhood development abnormalities in early onset schizophrenia: a case control study. 2011 , 11, 60	12
142	Weak association of the platelet-derived growth factor beta (PDGFB) and PDGF receptor beta (PDGFRB) genes with schizophrenia and schizoaffective disorder. 2011 , 12, 127-33	3
141	Increased Lymphocyte Caspase-3 Activity in Patients with Schizophrenia. 2011 , 30, 55-61	4
140	Genomics, Proteomics, and the Nervous System. <i>Advances in Neurobiology</i> , 2011 ,	2.1 1
139	Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample. 2011 , 25, 4011-23	25

138	The autoimmune model of schizophrenia. 2012 , 2012, 758072	4
137	A population-based study of shared genetic variation between premorbid IQ and psychosis among male twin pairs and sibling pairs from Sweden. 2012 , 69, 460-6	43
136	Multiple genes in the 15q13-q14 chromosomal region are associated with schizophrenia. 2012 , 22, 1-14	26
135	Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. 2012 , 17, 827-40	171
134	Glutamate and psychosis risk. 2012 , 18, 466-78	32
133	Glutamate receptor GRIN1 (GRID1) genetic variation and brain structure in schizophrenia. 2012 , 46, 1531-9	20
132	Engineering of substrate specificity of D-amino acid oxidase from the yeast <i>Trigonopsis variabilis</i> : directed mutagenesis of Phe258 residue. 2012 , 77, 1181-9	8
131	Animal models of schizophrenia emphasizing construct validity. 2012 , 105, 411-44	10
130	Effect of the interleukin-1 β gene on dorsolateral prefrontal cortex function in schizophrenia: a genetic neuroimaging study. 2012 , 72, 758-65	25
129	Multifaceted genomic risk for brain function in schizophrenia. 2012 , 61, 866-75	39
128	Haplotypes in the expression quantitative trait locus of interleukin-1 β gene are associated with schizophrenia. 2012 , 140, 185-91	25
127	A selective review of multimodal fusion methods in schizophrenia. 2012 , 6, 27	44
126	Association of P1635 and P1655 polymorphisms in dysbindin (DTNBP1) gene with schizophrenia. 2012 , 24, 155-9	4
125	Decreased axial diffusivity within language connections: a possible biomarker of schizophrenia risk. 2013 , 148, 67-73	25
124	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). 2013 , 6, 4-16	78
123	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). 2013 , 6, 4-16	3
122	Structural, phylogenetic and docking studies of D-amino acid oxidase activator (DAOA), a candidate schizophrenia gene. 2013 , 10, 3	24
121	Rhythmic theta and delta activity of cortical and hippocampal neuronal networks in genetically or pharmacologically induced N-methyl-D-aspartate receptor hypofunction under urethane anesthesia. 2013 , 237, 255-67	28

120	Progress in imaging the effects of psychosis susceptibility gene variants. 2013 , 13, 37-47	6
119	Schizotypy, cognitive performance, and genetic risk for schizophrenia in a non-clinical population. 2013 , 55, 334-338	8
118	Association study on the DLG4 gene and schizophrenia in the Chinese Han population. 2013 , 23, 247-50	1
117	An Integrative Bayesian Modeling Approach to Imaging Genetics. 2013 , 108,	21
116	GlyT-1 Inhibitors: From Hits to Clinical Candidates. 2014 , 51-99	8
115	New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways. 2014 , 8, 887-96	20
114	Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective. 2014 , 71, 2815-35	43
113	Latent inhibition of a conditioned taste aversion in fetal rats. 2014 , 56, 435-47	3
112	A Systematic Review of the Familial Co-Aggregation of Schizophrenia With Non-Psychotic Disorders. 2014 , 12, 280-301	2
111	Targeting of NMDA receptors in new treatments for schizophrenia. 2014 , 18, 1049-63	94
110	Subanalgesic ketamine enhances morphine-induced antinociceptive activity without cortical dysfunction in rats. 2014 , 28, 390-8	11
109	What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit. 2014 , 19, 1060-70	55
108	Association analysis of putative cis-acting polymorphisms of interleukin-19 gene with schizophrenia. 2014 , 50, 151-6	9
107	Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid. 2014 , 19, 228-34	45
106	Differential Effects of D-Cycloserine and ACBC at NMDA Receptors in the Rat Entorhinal Cortex Are Related to Efficacy at the Co-Agonist Binding Site. 2015 , 10, e0133548	8
105	Role of presynaptic phosphoprotein synapsin II in schizophrenia. 2015 , 5, 260-72	13
104	A systematic review of the effect of genes mediating neurodevelopment and neurotransmission on brain morphology: Focus on schizophrenia. 2015 , 21, 1-26	3
103	Evidence for schizophrenia susceptibility alleles in the Indian population: An association of neurodevelopmental genes in case-control and familial samples. 2015 , 162, 112-7	21

102	Clinical management of negative symptoms of schizophrenia: An update. 2015 , 153, 135-47	42
101	Modulation of hippocampus-prefrontal cortex synaptic transmission and disruption of executive cognitive functions by MK-801. 2015 , 25, 1348-61	41
100	Recent genetic findings in schizophrenia and their therapeutic relevance. 2015 , 29, 85-96	124
99	Toxoplasma gondii and Schizophrenia: A Relationship That Is Not Ruled Out. 2016 ,	
98	Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. 2016 , 2016, 6378137	33
97	The PSD. 2016 , 125-147	2
96	A cis-eQTL in AHI1 confers risk to schizophrenia in European populations. 2016 , 632, 130-5	3
95	The cell cycle-related genes as biomarkers for schizophrenia. 2016 , 70, 85-91	14
94	Association of EPHB1 rs11918092 and EFNB2 rs9520087 with psychopathological symptoms of schizophrenia in Chinese Zhuang and Han populations. 2016 , 8, 306-308	5
93	Are there glutamate abnormalities in subjects at high risk mental state for psychosis? A review of the evidence. 2016 , 171, 166-75	22
92	Genetic Markers of Human Evolution Are Enriched in Schizophrenia. 2016 , 80, 284-292	60
91	7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings. 2017 , 81, 525-535	53
90	The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice. 2017 , 45, 912-921	10
89	Pharmacoinformatics and molecular docking studies reveal potential novel Proline Dehydrogenase (PRODH) compounds for Schizophrenia inhibition. 2017 , 26, 314-326	12
88	A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway. 2017 , 7,	10
87	Theranostic Biomarkers for Schizophrenia. 2017 , 18,	53
86	Overview of Drug Polypharmacology and Multitargeted Molecular Design. 2017 , 259-275	3
85	Increased serum levels and promoter polymorphisms of macrophage migration inhibitory factor in schizophrenia. 2018 , 83, 33-41	14

84	Decreased plasma levels of gasotransmitter hydrogen sulfide in patients with schizophrenia: correlation with psychopathology and cognition. 2018 , 235, 2267-2274	12
83	Higher-order language dysfunctions as a possible neurolinguistic endophenotype for schizophrenia: Evidence from patients and their unaffected first degree relatives. 2018 , 267, 63-72	12
82	Enzymatic activity of palmitoyl-protein thioesterase-1 in serum from schizophrenia significantly associates with schizophrenia diagnosis scales. 2019 , 23, 6512-6518	5
81	Accumulation of Circulating Cell-Free CpG-Enriched Ribosomal DNA Fragments on the Background of High Endonuclease Activity of Blood Plasma in Schizophrenic Patients. 2019 , 2019, 8390585	8
80	Polymorphism of DTNBP1 Gene P 1635 (Rs3213207) In Schizophrenic Javanese, Indonesia. 2019 , 18, 703-705	
79	Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate. 2020 , 87, 204-214	24
78	Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?. 2020 , 10,	6
77	Association Between Glutathione Peroxidase-1 (GPx-1) Polymorphisms and Schizophrenia in the Chinese Han Population. 2020 , 16, 2297-2305	6
76	EEG microstates as biomarker for psychosis in ultra-high-risk patients. 2020 , 10, 300	16
75	Deletion of the Mitochondrial Matrix Protein CyclophilinD Prevents Parvalbumin Interneuron Dysfunction and Cognitive Deficits in a Mouse Model of NMDA Hypofunction. 2020 , 40, 6121-6132	1
74	Serotonin and schizophrenia. 2020 , 31, 711-743	4
73	Serum zonulin and claudin-5 levels in patients with schizophrenia. 2021 , 271, 767-773	11
72	Characterization of Neural Activity Using Complex Network Theory. <i>Springer Theses</i> , 2021 ,	0.1
71	The Antipsychotic Drug Clozapine Suppresses the RGS4 Polyubiquitylation and Proteasomal Degradation Mediated by the Arg/N-Degron Pathway. 2021 , 18, 1768-1782	1
70	Antipsychotic Agents. 1-69	0
69	Interneuron Heterotopia in the Lis1 Mutant Mouse Cortex Underlies a Structural and Functional Schizophrenia-Like Phenotype. 2021 , 9, 693919	1
68	Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders. 2021 , 12, 703452	6
67	Biovalue in Human Brain Banking: Applications and Challenges for Research in Neurodegenerative Diseases. 2022 , 2389, 209-220	

66	Sensory gating is related to positive and disorganised schizotypy in contrast to smooth pursuit eye movements and latent inhibition. 2021 , 161, 107989	
65	The Fetal Origins of Adult Mental Illness. 2006 , 204-218	8
64	Status and Potential Therapeutic Importance of n ω Fatty Acids in Neuropsychiatric Disorders. 2009 , 293-332	0
63	Proteomics of the Anterior Cingulate Cortex in Schizophrenia. <i>Advances in Neurobiology</i> , 2011 , 381-398 2.1	2
62	Complexity and the Onset of Psychosis. 2013 , 317-333	1
61	Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. 2017 , 147-191	2
60	D-amino acid oxidase: structure, catalytic mechanism, and practical application. 2005 , 70, 40-54	3
59	Antipsychotic drugs. 2007 , 545-556	2
58	Schizophrenia and related disorders. 2012 , 259-286	1
57	Contribution of CB2 receptors in schizophrenia-related symptoms in various animal models: Short review. 2020 , 114, 158-171	7
56	Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression.	1
55	Genetic and environmental risk factors for schizophrenia. 2012 , 553-561	2
54	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. 2004 , 113, 1353-1363	345
53	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. 2004 , 113, 1353-63	154
52	Dysbindin-1 and schizophrenia: from genetics to neuropathology. 2004 , 113, 1255-7	35
51	Social Functioning in Schizophrenia Clinical Correlations. 2018 , 44, 151-156	2
50	Potential microbial origins of schizophrenia and their treatments. 2009 , 45, 305-18	2
49	Analysis of schizophrenia data using a nonlinear threshold index logistic model. 2014 , 9, e109454	3

48	Neuregulin-1 Gene and Schizophrenia, and its Negative Symptoms in an Iranian Population. <i>Iranian Journal of Psychiatry and Behavioral Sciences</i> , 2016 , 11,	1.3	0
47	Neurotransmission. 2007 , 81-100		2
46	Early biomarkers of psychosis. 2005 , 7, 17-29		26
45	Environmental risk factors for psychosis. 2005 , 7, 69-80		94
44	Clinical impact of recently detected susceptibility genes for schizophrenia. 2006 , 8, 79-84		13
43	Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?. 2006 , 8, 303-9		11
42	Nature and nurture in neuropsychiatric genetics: where do we stand?. 2010 , 12, 7-23		35
41	Genetic variation in the 3'-untranslated region of influences schizophrenia susceptibility. 2017 , 13, 1101-1108	2	
40	Schizophrenia and genomics: linking research to practice. 2007 , 45, 24-8		4
39	Schizophrenie [Aktueller Kenntnisstand zur Krankheit und ihren Ursachen. 2003 , 3-14		
38	Genetics of schizophrenia and the impact of neuropsychology. 2004 , 267-277		
37	Searching for inherited causes for schizophrenia: has progress been made?. 2004 , 233-244		
36	Neuentwicklungen in der Erforschung der Genetik der Schizophrenie. 2004 , 63-72		4
35	High-risk studies, brain development, and schizophrenia. 2004 , 432-454		
34	Schizophrenies : actualité étiopathogéniques et cliniques. 2005 , 189, 935-947		
33	3 Schizofrenie: ontwikkelingen vanuit biologisch-psychiatrisch perspectief. 2006 , 29-37		
32	Glycerophospholipids and Phospholipases A2 in Neuropsychiatric Disorders. 2007 , 341-366		
31	Genetik psychischer Störungen. 2008 , 71-108		

30 Reporting and Interpreting Results. **2008**, 275-292

29 Schizophrenia: Biological Mechanisms. 1

28 Emotion Recognition Deficits as a Neurocognitive Marker of Schizophrenia Liability. **2009**, 163-176

27 Integrating the Epidemiology and Pathogenesis of Schizophrenia from the Street to the Striatum: Integrating the Epidemiology and Pathogenesis of Schizophrenia. **2010**, 357-366

26 Disinhibition of Prefrontal Cortex Neurons in Schizophrenia. **2010**, 99-111

25 Genetic Studies of Schizophrenia. *Advances in Neurobiology*, **2011**, 333-380

2.1

24 Genetik bei psychischen Erkrankungen. **2011**, 127-165

23 A Region-Based Ontology of the Brain Ventricular System and Its Relation to Schizophrenia. *Advances in Geospatial Technologies Book Series*, **2012**, 255-272

0

22 Candidate Genes Involved in the Expression of Psychotic Symptoms: A Focus on Hallucinations. **2013**, 231-252

1

21 Genetics. *SpringerBriefs in Public Health*, **2013**, 33-41

0.1

20 Behavioral Phenotypes and Genetic Syndromes. *Autism and Child Psychopathology Series*, **2014**, 109-122

0.2

1

19 Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. **2016**, 1-45

18 Neuregulin-1 Gene and Schizophrenia, and its Negative Symptoms in an Iranian Population. *Iranian Journal of Psychiatry and Behavioral Sciences*, **2016**, 11,

1.3

0

17 Structure Modeling and Molecular Docking Studies of Schizophrenia Candidate Genes, Synapsins 2 (SYN2) and Trace Amino Acid Receptor (TAAR6). *Lecture Notes in Computer Science*, **2017**, 291-301

0.9

1

16 Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. **2017**, 1-45

15 Deletion of the mitochondrial matrix protein cyclophilin-D prevents parvalbumin interneuron dysfunction and cognitive deficits in a mouse model of NMDA hypofunction.

14 Introduction. *Springer Theses*, **2021**, 1-21

0.1

13 The Research Progresses of Cross-Cultural Psychiatry for the Uygur and Han Nationality Suffered from Schizophrenia. *Advances in Clinical Medicine*, **2020**, 10, 841-848

0

12	Das Konzept der Entwicklungsstörung in der Schizophrenie-Forschung. 2006 , 81-91		
11	Neurogenetik und die Genetik des Verhaltens. 1995 , 717-762		
10	Association Analysis Between Common Variants of the Gene and Three Mental Disorders in the Han Chinese Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2020 , 24, 649-657	1.6	0
9	Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes. <i>Journal of Psychiatry and Neuroscience</i> , 2004 , 29, 287-93	4.5	13
8	Premorbid characterization in schizophrenia: the Pittsburgh High Risk Study. <i>World Psychiatry</i> , 2004 , 3, 163-8	14.4	60
7	The Role of MicroRNAs in Human Diseases. <i>Avicenna Journal of Medical Biotechnology</i> , 2010 , 2, 161-79	1.4	266
6	A Study of the Association between SNP8NRG241930 in the 5' End of Neuroglin 1 Gene with Schizophrenia in a Group of Iranian Patients. <i>Cell Journal</i> , 2011 , 13, 91-6	2.4	4
5	Polymorphism of the CLDN5 gene and Schizophrenia in an Iranian Population. <i>Iranian Journal of Public Health</i> , 2014 , 43, 79-83	0.7	14
4	Bibliographie. 2016 , 228-242		
3	A CROSS-SECTIONAL STUDY OF THE QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA.. 2022 , 104-108		
2	NTNG2 Mutation: A candidate gene for a new brain-skin disorder with early neuropsychiatric manifestation? An analysis based on 3000 patients. <i>Acta Medica Alanya</i> ,		
1	  2011 , 4,		0